Medable Therapeutic Area Pathways
Source: Medable
![Novel therapeutics: gene and cell therapies, nanoparticles, and combination Novel therapeutics: gene and cell therapies, nanoparticles, and combination](https://vertassets.blob.core.windows.net/image/7c911187/7c911187-63f5-4cb8-996a-bf21dc9fec5f/375_250-collaborative_drug_research_450x300.jpg)
All therapeutic areas face unique challenges but the industry’s challenges are universal.
- Study Start-Up & Enrollment Delays
- Poor Participant Experience
- Inconsistent & Incomplete Data
- High Site Burden
- Lack of Representation
Proven Benefits of DCT Technology:
- Reduced clinical trial cycle times by up to 3 months
- Lower clinical trial screen failure rates
- Fewer clinical trial protocol amendments
- 5-14x NPV measured as the net benefit in total study costs versus upfront investment (phase II & III studies)
access the Brochure!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Tech Leader? Subscribe today.
Subscribe to Clinical Tech Leader
X
Subscribe to Clinical Tech Leader
This website uses cookies to ensure you get the best experience on our website. Learn more